Comparative effectiveness of dapagliflozin versus DPP-4 inhibitors on a composite endpoint of HbA1c, body weight, and blood pressure reduction. A Nationwide Real World Italian Multicentric Study
Confronto di efficacia tra dapagliflozin ed inibitori di DPP-4 su un endpoint composito di riduzione di HbA1c, peso corporeo e pressione arteriosa. studio nazionale italiano multicentrico retrospettivo
Pubblicazioni
- Morieri ML, Consoli A, Sesti G, Purrello F, Avogaro A, Fadini GP; DARWIN-FUP network. Comparative effectiveness of dapagliflozin vs DPP-4 inhibitors on a composite endpoint of HbA1c, body weight and blood pressure reduction in the real world. Diabetes Metab Res Rev. 2021 Jan;37(1):e3353.
- Morieri ML, Raz I, Consoli A, Rigato M, Lapolla A, Broglio F, Bonora E, Avogaro A, Fadini GP; DARWIN-FUP network. Short-term effectiveness of dapagliflozin versus DPP-4 inhibitors in elderly patients with type 2 diabetes: a multicentre retrospective study. J Endocrinol Invest. 2023 Jul;46(7):1429-1439.
